Concurrent

Concurrent Pharmaceuticals was a biotechnology company focused on the discovery and development of small molecule therapeutics for rare genetic diseases, particularly lysosomal storage disorders. The company utilized a proprietary pharmacological chaperone platform designed to stabilize misfolded proteins and restore their cellular function. Its lead programs targeted conditions such as Gaucher disease and Fabry disease by enhancing the activity of deficient enzymes. In 2006, Concurrent Pharmaceuticals was acquired by Amicus Therapeutics, which integrated Concurrent's technology and pipeline into its own rare disease portfolio.